Comprehensive Proteomics Analysis of Stressed Human Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention

Highlights
- Proteomics of cytokine-treated human islets identified GDF15 as a protective factor
- GDF15 levels were reduced in cytokine-treated islets by translational blockade
- GDF15 inhibited IL-1β+INF-γ-induced apoptosis of human islets and a β-cell line
- Administration of GDF15 prevented diabetes in non-obese diabetic mice

Authors
Ernesto S. Nakayasu, Farooq Syed, Sarah A. Tersey, ..., Carmella Evans-Molina, Raghavendra G. Mirmira., Thomas O. Metz

In Brief
Nakayasu et al. used a proteomics-based approach in human islets to study the T1D-related process of β-cell destruction. They found that pro-inflammatory cytokines lead to the suppression of GDF15 mRNA translation. The study also revealed that GDF15 promotes the protection of β cells and prevents diabetes onset in mice.
Comprehensive Proteomics Analysis of Stressed Human Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention

Ernesto S. Nakayasu,1,9 Farooq Syed,2,9 Sarah A. Tersey,2,8 Marina A. Gritsenko,1 Hugh D. Mitchell,1 Chi Yuet Chan,1 Ercument Dirice,3 Jean-Valery Turatsinze,2 Yi Cui,5,7 Rohit N. Kulkarni,3 Decio L. Eizirik,4 Wei-Jun Qian,1 Bobbie-Jo M. Webb-Robertson,1,6 Carmella Evans-Molina,2 Raghavendra G. Mirmira,2,8,10,* and Thomas O. Metz1,10,11,*

1Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
2Center for Diabetes and Metabolic Diseases and the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
3Department of Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Brigham and Women’s Hospital, and Harvard Stem Cell Institute, Boston, MA, USA
4ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium
5Environmental and Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA
6Computing and Analytics Division, Pacific Northwest National Laboratory, Richland, WA, USA
7Present address: Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA
8Present address: Kovler Diabetes Center and Department of Medicine, University of Chicago, Chicago, IL, USA
9These authors contributed equally
10Senior author
11Lead Contact
*Correspondence: mirmira@uchicago.edu (R.G.M.), thomas.metz@pnnl.gov (T.O.M.)
https://doi.org/10.1016/j.cmet.2019.12.005

SUMMARY

Type 1 diabetes (T1D) results from the progressive loss of β cells, a process propagated by pro-inflammatory cytokine signaling that disrupts the balance between pro- and anti-apoptotic proteins. To identify proteins involved in this process, we performed comprehensive proteomics of human pancreatic islets treated with interleukin-1β and interferon-γ, leading to the identification of 11,324 proteins, of which 387 were significantly regulated by treatment. We then tested the function of growth/differentiation factor 15 (GDF15), which was repressed by the treatment. We found that GDF15 translation was blocked during inflammation, and it was depleted in islets from individuals with T1D. The addition of exogenous GDF15 inhibited interleukin-1β+interferon-γ-induced apoptosis of human islets. Administration of GDF15 reduced by 53% the incidence of diabetes in NOD mice. Our approach provides a unique resource for the identification of the human islet proteins regulated by cytokines and was effective in discovering a potential target for T1D therapy.

INTRODUCTION

Type 1 diabetes (T1D) is a chronic disease that affects approximately 1.25 million people in the U.S. Insulin administration successfully ameliorates the symptoms of T1D, but it does not prevent or cure this devastating disease, which shortens the lifespan of those affected by more than 10 years (Atkinson et al., 2014; DiMeglio et al., 2018; Livingstone et al., 2015). Since T1D is caused by a gradual, autoimmune-mediated destruction of insulin-producing β cells in the pancreatic islet, immunotherapies have been extensively tested to prevent or arrest disease (Ehlers, 2016). Recent clinical trial efforts suggest that immunomodulation can delay disease onset in certain-risk individuals, but responses to drug therapy are typically heterogeneous and limited in duration (Herold et al., 2019). A major hurdle in this process is a lack of understanding around the response of pancreatic β cells during immune activation and disease evolution.

Context and Significance

Type 1 diabetes results from the apoptotic destruction of the insulin-producing pancreatic β cells by an autoimmune response. Here, researchers at Pacific Northwest National Laboratory and their collaborators identified a protein, growth/differentiation factor 15 (GDF15), as a β-cell protective factor. GDF15 blocked pro-inflammatory cytokine-mediated cell death of human islets and a β-cell line. GDF15 also reduced the autoimmune response and diminished the onset of diabetes in mice. Therefore, GDF15 is a potential target for developing a therapy for type 1 diabetes.
Pro-inflammatory cytokines, such as interferon (IFN)-γ, interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, can be potent mediators of β-cell destruction by amplifying cell-mediated inflammation, directly activating apoptotic signaling, and inducing pro-apoptotic proteins (Eizirik et al., 2008; Eizirik et al., 2012; Ramos-Rodriguez et al., 2019). In addition, these cytokines have been shown to contribute to apoptosis by inducing mitochondrial dysfunction and endoplasmic reticulum stress (Eizirik et al., 2013; Gurzov and Eizirik, 2011). To prevent massive tissue damage, the organism has feedback mechanisms that counterbalance the effects of the pro-inflammatory cytokines (Elenkov and Chrousos, 2002). These feedback mechanisms, however, seem to be altered in T1D, failing to prevent a strong and progressive decrease in the β-cell population (Campbell-Thompson et al., 2016; Gupta et al., 2014). We hypothesized that comprehensive proteomics analyses of the cytokine responses in human islets could identify key pathways in the β cell that are up- or downregulated, which could define new targets that could be exploited for the development of T1D therapies.

Using comprehensive proteomics analysis, we aimed to unveil the molecular signatures of cytokine-induced β cell signaling to identify factors that regulate the balance between cell death and survival. Human pancreatic islets were treated with a combination of the pro-inflammatory cytokines, IL-1β and IFN-γ, and submitted to an in-depth proteomic analysis, leading to the identification and quantification of approximately 11,000 proteins. Our data showed significant activation of pathways related to inflammation, antigen processing and presentation, apoptosis, and cytokine signaling. Based on these expression profiles, we identified and confirmed growth/differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine 1 [MIC-1] as an islet-protective factor. This study exemplifies the utility of advanced proteomics to elucidate signaling pathways and identify interesting factors or targets for mechanistic study and elucidates the mechanism of GDF15 synthesis regulation by pro-inflammatory cytokines, its function in blocking apoptotic signaling, and in vivo activity in preventing insulitis.

RESULTS

Comprehensive Proteomic Analysis of Human Pancreatic Islets Treated with Cytokines
To investigate the molecular responses to pro-inflammatory stress that lead to β-cell death, human pancreatic islets from each of 10 non-diabetic cadaveric donors were treated with or without 50 U/mL IL-1β + 1,000 U/mL IFN-γ for 24 h. Due to the limited number of channels in the tandem-mass tags (TMT) kit used, islet samples from 5 different donors, including the samples treated with cytokines and respective controls, were combined in one TMT set, whereas the samples from the other 5 donors were multiplexed in a second set. Each TMT set was fractionated by high-pH reversed-phase chromatography and analyzed by liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) (Figure 1A) (Pride repository: PXD009131). The proteomic analysis resulted in the identification and quantification of 11,324 proteins, of which 9,695 proteins were identified in both TMT experiments (Table S1; Figure 1B). A total of 387 of these proteins were consistently and significantly altered in abundance in response to the cytokine treatment in both TMT sets (Table S2; Figure 1C). To ensure the biological significance of the data, we performed a post hoc statistical power analysis. The average power with a paired sample size of 5 was 0.93 for both sets 1 and 2. Evaluating each protein for adequate power indicated that 87.7% of proteins in both sets had a power of greater than 0.8 to detect a fold change of 1.5 for sets 1 and 2, respectively. (Figures S1A and S1B). The power analysis confirmed that the size of the present study is appropriate to investigate even small changes in protein abundances in response to the cytokine treatment.

Multiplexing samples using TMT combined with extensive fractionation of peptides prior to LC-MS/MS analysis leads to comprehensive coverage of the proteome; however, it may also result in protein fold change compression (Ow et al., 2009). Therefore, to more accurately determine the extent of fold changes in protein abundances, we performed an independent, label-free proteomics analysis of islets from two additional donors. These samples had the same cytokine treatment and were digested with trypsin before being analyzed by a label-free 2D LC-MS/MS proteome approach (Figure S2C). Proteins such as E3 ubiquitin-protein ligase RNF213, fractalkine, and ubiquitin D had only modest (1.7 to 2.9) fold change (comparing the signal intensities of treated versus control samples) in the TMT-labeled experiment. However, in the label-free analysis, this difference was much larger (E3 ubiquitin-protein ligase RNF213, fractalkine, and ubiquitin D were only detected in samples after treatment) (Figure S2D), showing that the extent of regulation in protein expression is higher than detected in the TMT-labeled experiment. Notably, and despite the fold change compression, these proteins were correctly identified as regulated by the cytokine treatment.

The label-free proteomics experiment also served to validate the overall findings from the TMT-labeled analysis, since it was based on an independent experiment, i.e., the islets were obtained from two additional non-diabetic donors and treated with cytokines in a different laboratory using the same protocol. Furthermore, the samples were analyzed using an alternative proteomics pipeline without TMT labeling and an independent label-free quantification approach. In the label-free proteomics dataset, a total of 6,038 proteins were identified, including 207 of the 387 significantly regulated proteins found in the TMT-labeled proteomics experiment. Out of these 207 proteins, 182 (88%) were regulated in the same direction compared to proteins identified in the TMT-labeled proteomics experiment (Figures S2D and S2E). Overall, this independent analysis cross-validated a large portion of the proteins found to be significantly regulated by the IL-1β + IFN-γ treatment and showed that some of the proteins found to be differentially expressed in the first experiment were even more markedly modified than initially assumed.

Cellular Pathways Regulated by the IL-1β + IFN-γ Treatment
We next performed a function-enrichment analysis using the DAVID database to determine pathways regulated by the cytokine treatment. A total of 49 pathways were significantly enriched with cytokine-regulated proteins (Figure 1D). To facilitate interpretation, we clustered different pathways into

364 Cell Metabolism 31, 363–374, February 4, 2020
main biological processes based on their overlapping signaling (shared proteins) as previously described (Merico et al., 2010). The analysis revealed that the cytokine treatment regulated proteins related to NF-κB signaling, cytokine-cytokine receptor interactions, apoptosis, antigen processing and presentation, extracellular matrix, coagulation and complement cascades, rheumatoid arthritis, and transcriptional misregulation in cancer (Figure 1D). Because β-cell death was the main phenotype of interest in our study, we next performed a more detailed analysis of proteins related to apoptosis using the MetaCore tool, which led to the assignment of 88 differentially abundant proteins to this function, of which 73 (83%) were annotated to be physically or functionally interacting with each other (Figure S1F). Of note, most of the proteins in this pathway were upregulated with the treatment, while some potential inhibitors of apoptosis, such as thrombospondin 1 (Cunha et al., 2017), were downregulated. This observation supports the hypothesis that pro-inflammatory cytokines induce cell death by breaking the homeostatic balance between pro- and anti-apoptotic factors.

Another pathway that drew our attention was the cytokine-cytokine receptor interaction because this indicated that the IL-1β + IFN-γ treatment regulates the expression of cytokines and receptors that might result in sequential, feedforward signaling events in the cells. Importantly, these types of molecules are pharmaceutically active, making them potential candidates for therapies. The present proteomics analysis detected and identified 54 cytokines, chemokines, and growth factors, of which 19 were regulated by IL-1β + IFN-γ. Out of these regulated cytokines, chemokines, and growth factors, 16 were upregulated, while only 3 were downregulated (Figure 2A). Taken together, the proteomic analysis showed a significant regulation of proteins related to cytokine signaling and apoptosis in pancreatic islets treated with pro-inflammatory cytokines.

**Abundance Profiles of Selected Proteins in Cells and In Vivo**

To identify possible therapeutic targets, we prioritized proteins to be further studied based on four criteria: (1) regulation in response to the IL-1β + IFN-γ treatment, (2) function in apoptosis, (3) classification as cytokines, chemokines, or growth factors, and (4) validation by the label-free proteomic analysis. Only 5 proteins matched all these criteria: fractalkine, IL-1α, IL-1β, osteopontin (secreted phosphoprotein 1 [SPP1]), and growth/differentiation factor 15 (GDF15). Of those cytokines, SPP1 and GDF15 were chosen for further study because there was limited information about their role in T1D, yet they have been described as regulating different aspects of the immune system.

![Figure 1. Global Proteomic Analysis of Human Pancreatic Islets Treated with IFN-γ and IL-1β Using Tandem Mass Tags](image)
response (Artz et al., 2016; Bootcov et al., 1997; Cai et al., 2018; Clemente et al., 2016; Kahles et al., 2014). We first validated cytokine-mediated downregulation of SPP1 and GDF15 by treating the EndoC-βH1 human β-cell line and the mouse MIN6 β-cell line with IL-1β + IFN-γ. Immunoblot analysis confirmed the reduction in SPP1 and GDF15 protein expression in response to cytokine treatment by 25% and 35%, respectively, in EndoC-βH1 cells (Figure 2B). Similar results were observed in MIN6 cells (Figure 2C). We next analyzed the expression of GDF15 and SPP1 in human islets treated with IL-1β + IFN-γ (Figure 2A). Both proteins were significantly reduced in response to cytokine treatment: GDF15 was downregulated by 70%, and SPP1 was reduced by approximately 60% (Figure 3A). These data were confirmed by immunoblot analysis, which showed a reduction of approximately 20% and 60% in the levels of SPP1 and GDF15, respectively (Figures 3A and S2). Consistent with a likely transcriptional mechanism of regulation, levels of the mRNA encoding SPP1 were coordinately decreased by about 70% by cytokine treatment (Figure 3A). By contrast, levels of the mRNA encoding GDF15 were increased two-fold by cytokine treatment, suggesting a regulation of this protein at the post-transcriptional level. We then investigated whether this phenomenon was restricted to GDF15 by comparing the expression of the 387 proteins regulated by IL-1β + IFN-γ to their corresponding mRNA levels from a transcriptomics analysis of human islets exposed to the same cytokines (Eizirik et al., 2012). Among the proteins whose expression increased following cytokine treatment, 65% showed a synchronized increase in their corresponding mRNAs (Figure 3B). In contrast, only 35% of the downregulated proteins showed a significant decrease in their transcript levels (Figure 3B). Together, these results suggest that several pathways, including cytokine-receptor interaction, antigen presentation, and apoptosis, are regulated by the IL-1β + IFN-γ treatment in human islets. The results also demonstrated a downregulation of GDF15 and SPP1 in β cells, a finding that was also observed in murine islets with insulitis in vivo.

Mechanism Regulating GDF15 and SPP1 Expression in Human Islets

Pro-inflammatory cytokines can regulate the levels of proteins by a variety of mechanisms, ranging from transcription and translation to protein degradation and secretion (Carpenter et al., 2014). To investigate possible regulatory mechanisms, we compared the protein and transcript levels of GDF15 and SPP1 in human islets treated with IL-1β + IFN-γ. Both proteins were significantly reduced in response to cytokine treatment: GDF15 was downregulated by 70%, and SPP1 was reduced by approximately 60% (Figure 3A). These data were confirmed by immunoblot analysis, which showed a reduction of approximately 20% and 60% in the levels of SPP1 and GDF15, respectively (Figures 3A and S2). Consistent with a likely transcriptional mechanism of regulation, levels of the mRNA encoding SPP1 were coordinately decreased by about 70% by cytokine treatment (Figure 3A). By contrast, levels of the mRNA encoding GDF15 were increased two-fold by cytokine treatment, suggesting a regulation of this protein at the post-transcriptional level. We then investigated whether this phenomenon was restricted to GDF15 by comparing the expression of the 387 proteins regulated by IL-1β + IFN-γ to their corresponding mRNA levels from a transcriptomics analysis of human islets exposed to the same cytokines (Eizirik et al., 2012). Among the proteins whose expression increased following cytokine treatment, 65% showed a synchronized increase in their corresponding mRNAs (Figure 3B). In contrast, only 35% of the downregulated proteins showed a significant decrease in their transcript levels (Figure 3B). Together, these...
data suggest that decreases in protein abundance are more likely to be independent of reduction in transcriptional rates, whereas increases in protein expression correspond to coordinate increases in mRNAs.

Several posttranscriptional mechanisms might account for regulation of protein levels, including alterations at the level of ribosome engagement during mRNA translation, for instance, secondary to ER stress (Carpenter et al., 2014). To test whether the decrease in GDF15 protein level during cytokine treatment was due to a block in GDF15 mRNA translation, we performed polyribosomal profiling experiments (Templin et al., 2014). Results from polyribosomal profiling showed that during cytokine treatment, GDF15 mRNA was found mostly in the monoribosomal fractions, as measured by qPCR (Figures 3C and 3D). These results indicate that GDF15 mRNA translation is blocked by treatment with pro-inflammatory cytokines.

**GDF15 Protects β Cells from IL-1β- and IFN-γ-Induced Cell Death**

As shown in Figure S2, not all proteins in the apoptotic pathway were upregulated with the cytokine treatment. We hypothesized that downregulated proteins in this pathway could be anti-apoptotic factors, since the treatment induces cell death. To test this hypothesis, we first performed a network analysis with the Metacore tool of the downstream signaling regulated by GDF15 and SPP1. This analysis showed some overlap on the signaling transduction pathways, with both GDF15 and SPP1 signaling converging to regulating apoptosis (Figure 4A), thereby...
indicating their potential on regulating cell death. We then pre-
treated the human insulin-producing EndoC-βH1 cells with
50 ng/mL of recombinant SPP1 (rSPP1) or 100 ng/mL of recom-
binant GDF15 (rGDF15) for 12–16 h followed by treating with
IFN-γ + IL-1β for another 24 h. Apoptosis was assessed by west-
er blot analysis of cleaved caspase 3. As expected, IFN-γ +
IL-1β treatment alone induced apoptosis as indicated by 3-fold
increase in the amount of cleaved caspase 3 (Figures 4B–4D).
Pretreatment with GDF15 and SPP1, however, led to an
50% reduction in cleaved caspase 3 (Figures 4B–4D). We performed
similar treatment of human islets and measured caspase 3/7
activity by a luminescence assay, which confirmed a complete
protection by rGDF15 and rSPP1 pre-treatment against cyto-
kine-induced apoptosis (Figure S3). Therefore, we conclude that
GDF15 and SPP1 protect EndoC-βH1 cells and human islets
from apoptosis induced by exposure to IFN-γ + IL-1β.

GDF15 Inhibits Insulitis and
Decreases Incidence of Diabetes in
NOD Mice
After determining that GDF15 protected β-cells from IFN-γ + IL-1β-induced apoptosis, we addressed the question of whether it
could also protect pancreatic islets in vivo. Therefore, we treated 6-week-old female NOD mice (n = 5) every two days for two
weeks with rGDF15 or vehicle alone. The body weight and blood glucose levels were monitored over the treatment period
and were shown to be stable and unaf-
fected by the GDF15 administration (Figures 5A and 5B), which
is expected since at this stage, NOD mice are not yet hyperglyce-
mic. After the treatment period, mice were euthanized and pan-
creata were excised for histopathological analysis. This analysis
showed a significant decrease in insulitis of GDF15-treated mice
compared to the control group (Figures 5C and 5D). The decrease
in insulitis was accompanied by a reduction in oxidative stress,
as shown by immunostaining of the lipid peroxidation marker,
4-hydroxynonenal (4HNE) (Figure 5E). Having shown that GDF15
reduced insulitis, we hypothesized that it could also prevent or
delay the incidence of diabetes. To test this hypothesis, 6-week-
old NOD mice (n = 20) were treated with rGDF15 every 2 days
for 4 weeks and monitored for up to 24 weeks of age for the devel-
opment of diabetes (defined as blood glucose > 250 mg/dL on two
consecutive measurements). GDF15 treatment reduced by 53%
(p = 0.006) the incidence of diabetes in these mice (Figure 6). Over-
all, these data show a reduction in insulitis and oxidative stress
by GDF15 in vivo, leading to reduced incidence of diabetes in
NOD mice.
GDF15 Levels in Pancreatic Sections of Individuals with Diabetes

Finally, to validate our findings from in vitro and in vivo models in human T1D, we investigated the levels of GDF15 in pancreas from donors with diabetes. The immunostaining analysis showed that GDF15 was present in different parts of the pancreas but with relatively higher abundance in islets (Figure 7A, row 1). Islets from donors with T1D exhibited an ~10-fold reduction in GDF15 abundance (Figures 7A, rows 2 and 3, and 7B). Two of the donors with T1D had residual insulin abundance and decreased but still detectable levels of GDF15 (Figures 7A, row 3, and 7B). On the other hand, islets from individuals with T2D and from individuals with no diabetes had similar abundance of GDF15 (Figures 7A, row 4, and 7B).

For comparison, no significant changes in the levels of glucagon abundance were observed in islets from donors with T1D or T2D compared to the control group. Taken together, our data showed that the abundance of GDF15 is reduced in islets of individuals with T1D, similar to what we found with islets treated with pro-inflammatory cytokines and in islets from NOD mice with insulitis.

DISCUSSION

In this paper, we aimed to test the balance between pro- and anti-apoptotic signaling induced by cytokines in the context of β-cell death by performing a comprehensive proteomics analysis of cytokine-treated islets. In our study, we leveraged recent advances in mass spectrometry-based proteomics to enable the detection of many extremely low abundance proteins, such as cytokines, chemokines, and growth factors, providing a more complete picture of the pathways regulated by pro-inflammatory cytokines in human islets. This deep proteomics coverage resulted in the precise identification and quantification of over 11,000 proteins in human islets. Overall, the treatment revealed a strong regulation of pathways such NF-κB signaling, cytokine-cytokine receptor interaction, apoptosis, and antigen processing and presentation. Supporting the hypothesis that β cells die due to an imbalance between pro- and anti-apoptotic factors, well-described apoptotic activators, such as PTPN2 and STAT1 (Santin et al., 2011; Suk et al., 2001), were upregulated with the treatment, whereas SPP1 and connective tissue growth factor (CTGF), proteins described to protect and regenerate β cells, respectively (Guney et al., 2011; Lyssenko et al., 2011), were downregulated after the IFN-γ + IL-1β treatment.

To further investigate the balance between pro- and anti-apoptotic factors, we next studied the mechanism of GDF15 downregulation due to IFN-γ + IL-1β treatment, since GDF15 had previously been shown to inhibit apoptosis in endothelial cells (Li et al., 2013). We showed that GDF15 abundance was reduced in cytokine-treated human islets and in human and rodent β cell lines by translational blockade. This phenomenon seems to be extensive and not restricted to GDF15, since only 35% of the downregulated proteins were regulated at the transcriptional level. In terms of GDF15 regulation, this gene is post-transcriptionally regulated in murine macrophages by...
tristetraprolin (TTP or ZFP36), an RNA-binding protein that targets transcripts containing adenylate-uridylate (AU)-rich elements (AREs) for degradation (Tiedje et al., 2016). TTP is indeed a major regulator of the inflammatory response by targeting cytokine mRNAs to degradation, as these transcripts often bear AREs (Sedlyarov et al., 2016). TTP has also been shown to bind and prevent specific transcripts to be translated (Brooks and Blackshear, 2013), but its role in regulating GDF15 levels in the islets requires further investigation. Of note, TTP mRNA expression is increased by >2-fold (p < 0.05) following IFN-γ + IL-1β treatment of human islets, as evaluated by RNA sequencing of two different batches of human islet preparations (n = 5 each) (Eizirik et al., 2012; Gonzalez-Duque et al., 2018).

We next showed that GDF15 inhibited cytokine-induced apoptosis of human islets and a β-cell line. GDF15 was first reported to act as an anti-inflammatory cytokine that decreases the production of TNF-α in macrophages activated with bacterial lipopolysaccharide (Bootcov et al., 1997). The anti-apoptotic property of GDF15 is not surprising, since it inhibits inflammation, a process that often triggers apoptosis. Indeed, anti-apoptotic effects of GDF15 have been documented in other tissues (Heger et al., 2010; Schiegnitz et al., 2012), but they have not been studied in islets yet. In terms of signaling, the GDF15 receptor was recently identified to be GDNF family receptor α-like (GFRAL), which requires co-receptor RET to elicit intracellular signaling (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). Despite the deep coverage of our proteomic analysis, GFRAL and RET proteins were not detected, which indicates that these proteins might be expressed at very low levels. There is also a possibility that GDF15 interacts with a different receptor or that it inhibits pro-apoptotic signaling by other mechanisms. For instance, Luan et al. showed that GDF15 induces immune tolerance in acute infections and sepsis through mobilization of triacylglycerols from the liver, which reduces inflammation systemically (Luan et al., 2019). GDF15 has also been shown to inhibit angiogenesis by interacting and blocking CTGF signaling (Whitson et al., 2013). Interestingly, GDF15 and CTGF have been shown to be co-regulated in cardiac fibrosis and jejunum damage (Krusche et al., 2011; Yu et al., 2010), which was also observed in human islets treated with IL-1β + IFN-γ (Figure 2A). However, the role of this co-regulation in preventing β-cell apoptosis remains to be clarified.

GDF15 has been associated with a variety of metabolic syndrome-related diseases, such as cardiovascular diseases, obesity, and type 2 diabetes (Unsicker et al., 2013), and is a marker of myocardial infarction and a prognostic factor of heart failure (Khan et al., 2009). Increased levels of GDF15, however, do not seem to be a causative factor for heart failure but rather a consequence of the cellular responses aimed at repairing damaged heart muscle (Kempf et al., 2011). Indeed, molecular studies have shown that GDF15 protects the heart from fatal rupture after myocardial infarction (Kempf et al., 2011). In obesity, GDF15 was first associated with anorexia-cachexia of cancer patients, likely as the consequence of overexpression of this protein by tumor or tumor-associated immune cells (Tsai et al., 2016), observations that were fundamental for the discovery of its functions in controlling body weight. High levels of GDF15 activate the GFRAL receptor in the hindbrain, reducing appetite and food intake and promoting weight loss (Chung et al., 2017; Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). In addition, GDF15 was shown to be an important signal in response to nutrition stress induced by long-term high-fat feeding or dietary amino acid imbalance (Patel et al., 2019). In diabetes, increased levels of GDF15 are present in the plasma of individuals with T2D, but this phenomenon seems to be independent of the incidence of the disease (Carstensen et al., 2010). Moreover, GDF15 improves insulin sensitivity in mice fed a high-fat chow (Chung et al., 2017; Jung et al., 2018; Lee et al., 2017), showing its potential for treating T2D. Our data add another element to this growing literature; namely, it indicates a directly protective effect of GDF15 against cytokine-induced β-cell apoptosis. This protection was also observed in vivo, as GDF15 administration reduced by 53% the incidence of diabetes in NOD mice. Although it is difficult to make a direct comparison due to differences in the treatment regimens, similar levels of protection were observed for anti-CD3, α-3 fatty acid, and palmitic acid esters of hydroxy stearic acid treatments (Bi et al., 2017; Bresson et al., 2006; Syed et al., 2019).

In conclusion, we present a unique resource for the identification of human islet proteins regulated by pro-inflammatory cytokines. By mining this new dataset, and integrating it with available RNA sequencing data, we detected an imbalance between pro- and anti-apoptotic proteins modulated by IL-1β + IFN-γ in β cells. This imbalance includes a post-transcriptional downregulation of GDF15, presently shown to act as an anti-apoptotic protein. This finding provides a proof of concept for the utility of the present resource. Additional extension and mining of the human islet proteome has the potential to indicate novel avenues for the therapy of diabetes.

**Limitations of Study**

Here, we have shown that GDF15 can prevent IL-1β + IFN-γ-induced apoptosis in human islets and EndoC-βH1 cells. We also showed that it can inhibit insulin and partially prevent diabetes in NOD mice. However, a limitation of the study is the lack of understanding of the GDF15 mechanism of action. We showed that GDF15 has effects directly in human islets...
and EndoC-βH1 cells, but its receptor, GFRAL, is currently thought to be only expressed in the hindbrain (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). Therefore, additional work needs to be done to determine whether GDF15 has a receptor in human islets or if it acts through a systemic action of the hindbrain.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Human Islets
  - EndoC-βH1 Human β Cell Line
  - MIN6 Murine β Cell Line
  - Mice
  - Human Pancreas
- METHOD DETAILS
  - Pancreatic Islet Culture and Treatment
  - Proteomic Analysis Using Tandem Mass Tags

Figure 7. Expression of GDF15 in Human Pancreas

(A) Pancreas tissue sections from normoglycemic human donors and from those diagnosed with T1D and T2D were stained for DNA, insulin, glucagon, and GDF15. IDs represent donor identification numbers from the Network for Pancreatic Organ Donors with Diabetes (nPOD) (Table S4). Scale bars represent 20 μm.

(B) Quantification of staining intensities of insulin, glucagon, and GDF15. ANOVA Test: *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001.
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.cmet.2019.12.005.

ACKNOWLEDGMENTS


DATA AND CODE AVAILABILITY

Received: September 12, 2018
Revised: September 3, 2019
Accepted: December 12, 2019
Published: January 9, 2020

REFERENCES


## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-cleaved caspase 3</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9664; RRID:AB_2070042</td>
</tr>
<tr>
<td>Anti-caspase 3</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9662; RRID:AB_331439</td>
</tr>
<tr>
<td>Anti-GDF15</td>
<td>Bioss</td>
<td>Cat# bs-3818R; RRID:AB_10857699</td>
</tr>
<tr>
<td>Anti-SPP1</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# PA5-34579; RRID:AB_2551931</td>
</tr>
<tr>
<td>Anti-Tubulin</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2128; RRID:AB_823664</td>
</tr>
<tr>
<td>Anti-rabbit IgG</td>
<td>Li-Cor Biosciences</td>
<td>Cat# 926-68073; RRID:AB_10954442</td>
</tr>
<tr>
<td>Anti-mouse IgG</td>
<td>Li-Cor Biosciences</td>
<td>Cat# 926-32212; RRID:AB_621847</td>
</tr>
<tr>
<td>Anti-insulin</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat# sc-9168; RRID:AB_2126540</td>
</tr>
<tr>
<td>Peroxidase conjugated anti-rabbit IgG</td>
<td>Vector Labs</td>
<td>Cat# MP-7401; RRID:AB_2336529</td>
</tr>
<tr>
<td>Anti-Glucagon</td>
<td>Abcam</td>
<td>Cat# ab10988; RRID:AB_297642</td>
</tr>
<tr>
<td>Anti-insulin</td>
<td>Agilent</td>
<td>Cat# A0564; RRID:AB_10013624</td>
</tr>
<tr>
<td>Anti-4-HNE</td>
<td>Abcam</td>
<td>Cat# ab46545; RRID:AB_722490</td>
</tr>
<tr>
<td>goat anti-guinea pig (Alexa Fluor-488)</td>
<td>Molecular Probes</td>
<td>Cat# A-11073; RRID:AB_2534117</td>
</tr>
<tr>
<td>donkey anti-rabbit (Alexa Fluor-568)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# A10042; RRID:AB_2534017</td>
</tr>
<tr>
<td>donkey anti-mouse(Alexa Fluor-647)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# A-21240, RRID:AB_2535809</td>
</tr>
<tr>
<td>donkey anti-rabbit (IRDy®/800CW)</td>
<td>LI-COR Biosciences</td>
<td>Cat# 926-32213; RRID:AB_621848</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Fisher</td>
<td>MT61277RG</td>
</tr>
<tr>
<td>Penicillin Streptomycin</td>
<td>Life Technologies Ltd</td>
<td>15140-122</td>
</tr>
<tr>
<td>Standard Islet Medium</td>
<td>Prodo</td>
<td>PIM-S001GMP</td>
</tr>
<tr>
<td>human AB serum</td>
<td>Prodo</td>
<td>PIM-ABS001GMP</td>
</tr>
<tr>
<td>Glutamine and Glutathione Supplement</td>
<td>Prodo</td>
<td>PIM-G001GMP</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium</td>
<td>Life Technologies Ltd</td>
<td>11965-092</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium</td>
<td>Life Technologies Ltd</td>
<td>11885-084</td>
</tr>
<tr>
<td>ECM</td>
<td>Sigma-Aldrich</td>
<td>E1270</td>
</tr>
<tr>
<td>Fibronectin from bovine plasma</td>
<td>Sigma-Aldrich</td>
<td>F1141</td>
</tr>
<tr>
<td>Nicotinamide</td>
<td>Sigma-Aldrich</td>
<td>N0636-100G</td>
</tr>
<tr>
<td>Sodium selenite</td>
<td>Sigma-Aldrich</td>
<td>S8132</td>
</tr>
<tr>
<td>Human Transferrin</td>
<td>Sigma-Aldrich</td>
<td>T8158</td>
</tr>
<tr>
<td>Fatty Acid Free heat shock BSA powder</td>
<td>Equitech</td>
<td>BAH66</td>
</tr>
<tr>
<td>Beta-2-mercaptoethanol</td>
<td>Fisher BioReagents</td>
<td>O34461-100</td>
</tr>
<tr>
<td>Recombinant IL-1β</td>
<td>R and D systems</td>
<td>201-LB-005</td>
</tr>
<tr>
<td>Recombinant IFN-γ</td>
<td>R and D systems</td>
<td>285-IF-100</td>
</tr>
<tr>
<td>Recombinant SPP1</td>
<td>GenTex</td>
<td>GTX48134-PRO</td>
</tr>
<tr>
<td>Halt phosphatase inhibitor cocktail</td>
<td>Thermo Fisher Scientific</td>
<td>78420</td>
</tr>
<tr>
<td>Sodium fluoride</td>
<td>Sigma</td>
<td>S7920</td>
</tr>
<tr>
<td>Urea</td>
<td>Sigma</td>
<td>U0631</td>
</tr>
<tr>
<td>Ammonium Bicarbonate</td>
<td>Sigma</td>
<td>9830</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>Sigma</td>
<td>C1016</td>
</tr>
<tr>
<td>Tandem mass tags - 10plex</td>
<td>Thermo Fisher Scientific</td>
<td>90110</td>
</tr>
<tr>
<td>Dithiothreitol</td>
<td>Thermo Fisher Scientific</td>
<td>20291</td>
</tr>
<tr>
<td>Iodoacacetamide</td>
<td>Thermo Fisher Scientific</td>
<td>90034</td>
</tr>
<tr>
<td>Ammonium Formate</td>
<td>Sigma</td>
<td>9735</td>
</tr>
<tr>
<td>Formic acid</td>
<td>Sigma</td>
<td>33015</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>C18 SPE cartridge, Discovery, 50 mg</td>
<td>Supelco</td>
<td>52601-U</td>
</tr>
<tr>
<td>D-Sucrose</td>
<td>Fisher Bio Reagent</td>
<td>BP220-212</td>
</tr>
<tr>
<td>Cycloheximide solution</td>
<td>Sigma</td>
<td>C4859-1ML</td>
</tr>
<tr>
<td>Recombinant RNasin® Ribonuclease Inhibitor</td>
<td>Promega</td>
<td>N2515</td>
</tr>
<tr>
<td>Benzonase® Nuclease</td>
<td>Edmillipore</td>
<td>70746-3</td>
</tr>
<tr>
<td>Human GDF15 Protein (His Tag) – Produced in yeast; the absence of TGF-β contamination was confirmed by ELISA (R&amp;D system; Cat#MB100B).</td>
<td>Sino Biologicals</td>
<td>10936-H07Y</td>
</tr>
<tr>
<td>Human GDF15 Protein – Produced in E. coli, endotoxin tested: &lt; 1 EU/μg protein by LAL assay; the absence of TGF-β contamination was confirmed by ELISA (R&amp;D system; Cat#MB100B).</td>
<td>ProSpec</td>
<td>cyt-335</td>
</tr>
<tr>
<td>Annexin A5 FITC / 7-AAD Kit</td>
<td>Beckman Coulter</td>
<td>IM36154</td>
</tr>
<tr>
<td>Mini-PROTEAN TGX Gels</td>
<td>BIO-RAD</td>
<td>456-1094</td>
</tr>
<tr>
<td>10X- Tris/Glycine/SDS Buffer</td>
<td>BIO-RAD</td>
<td>161-0772</td>
</tr>
<tr>
<td>10X- Tris/Glycine Buffer</td>
<td>BIO-RAD</td>
<td>161-0771</td>
</tr>
<tr>
<td>Signal Enhancer HIKARI 250 (Solution 1 &amp; Solution 2)</td>
<td>Nacalai U.S.A</td>
<td>NU00102</td>
</tr>
<tr>
<td>Critical Commercial Assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caspase-Glo 3/7 assay kit</td>
<td>Promega</td>
<td>G8090</td>
</tr>
<tr>
<td>RNeasy plus mini kit</td>
<td>QIAGEN</td>
<td>74134</td>
</tr>
<tr>
<td>M-MLV RT kit</td>
<td>Invitrogen</td>
<td>28025013</td>
</tr>
<tr>
<td>TaqMan Gene Expression Master mix</td>
<td>Applied biosystems</td>
<td>4369016</td>
</tr>
<tr>
<td>Apo-ONE Homogeneous Caspase-3/7 Assay</td>
<td>Promega</td>
<td>G7790</td>
</tr>
<tr>
<td>Deposited Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proteomics data</td>
<td>Pride repository</td>
<td>PXD009131</td>
</tr>
<tr>
<td>Experimental Models: Cell Lines and Tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human: EndoC-jH1 cells</td>
<td>Dr. R. Scharfman (University of Paris, France)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: MIN6</td>
<td>J. Miyazaki (Japan)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: pancreatic islets</td>
<td>Integrated Islet Distribution Program (IIDP)</td>
<td>N/A</td>
</tr>
<tr>
<td>Human: pancreas tissue sections</td>
<td>Network for Pancreatic Organ Donors with Diabetes (nPOD)</td>
<td>N/A</td>
</tr>
<tr>
<td>Experimental Models: Organisms/Strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: NOD/ShiLTJ (NOD)</td>
<td>Jackson Laboratories</td>
<td>1976</td>
</tr>
<tr>
<td>Oligonucleotides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GDF15</td>
<td>TaqMan</td>
<td>Cat# 4448892; ID Hs00171132_m1</td>
</tr>
<tr>
<td>SPP1</td>
<td>TaqMan</td>
<td>Cat# 4331182; Hs00959010_m1</td>
</tr>
<tr>
<td>β-actin</td>
<td>TaqMan</td>
<td>Cat# 4333762F; ID Hs01060665_g1</td>
</tr>
<tr>
<td>Software and Algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSGF+</td>
<td>Pevzner Lab, University of California - San Diego</td>
<td><a href="https://doi.org/10.1038/ncomms6277">https://doi.org/10.1038/ncomms6277</a></td>
</tr>
<tr>
<td>MASIC</td>
<td>Omics Group, Pacific Northwest National Laboratory</td>
<td><a href="https://doi.org/10.1016/j.compbiochem.2008.02.006">https://doi.org/10.1016/j.compbiochem.2008.02.006</a></td>
</tr>
<tr>
<td>Decon2LS_V2</td>
<td>Omics Group, Pacific Northwest National Laboratory</td>
<td><a href="https://doi.org/10.1186/1471-2105-10-87">https://doi.org/10.1186/1471-2105-10-87</a></td>
</tr>
<tr>
<td>DTARefinery</td>
<td>Omics Group, Pacific Northwest National Laboratory</td>
<td><a href="https://doi.org/10.1074/mcp.M900217-MCP200">https://doi.org/10.1074/mcp.M900217-MCP200</a></td>
</tr>
<tr>
<td>MaxQuant v.1.5.3.28</td>
<td>Cox Lab, Max-Planck Institute for Biochemistry</td>
<td><a href="https://doi.org/10.1038/nprot.2016.136">https://doi.org/10.1038/nprot.2016.136</a></td>
</tr>
</tbody>
</table>

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Requests for further information and resources should be directed to and will be fulfilled by the Lead Contact, Thomas Metz (thomas.metz@pnnl.gov). Proteomics data are available as described below. No other reagents or resources were generated as a part of this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human Islets
Pancreatic islets from cadaveric donors were acquired from the Integrated Islet Distribution Program (IIDP) (Brissova et al., 2019). Because the tissues came from cadaveric donors, the study was not considered human subjects research, and no consent was required.

The characteristics of the tissue donors are listed in Table S3. The mean and standard deviation in age of the donors was 44.1 ± 12.8 years. The mean and standard deviation in BMI of the donors was 28.9 ± 5.1. Islets were obtained from 15 males and 12 females.

To ensure the biological significance of the data we performed a post hoc statistical power analysis. The average power with a paired sample size of 5 was 0.93 for both proteomics sets 1 and 2. Evaluating each protein for adequate power indicated that 87.7% of proteins in both sets had a power of greater than 0.8 to detect a fold-change of 1.5 for sets 1 and 2, respectively. (Figures S1A and S1B). The power analysis confirmed that the size of the present study is appropriate to investigate even small changes in protein abundances in response to the cytokine treatment.

An analysis of the influence of sex on the results of the study was not performed, since there was not adequate power in the study to address this question.

Human islets were received from IIDP as described above and were required to have a minimum of 85% purity as measured by dithizone and 90% viability. Islets were maintained in Standard Islet Medium (Prodo) supplemented with human AB serum (Prodo), Ciprofloxacin (Fisher) and glutamine and glutathione (Prodo) at 37°C, under 100% humidity and 5% CO2 atmosphere. To study the protective effect of GDF15 and SPP1, we pretreated islets with human recombinant 100 ng/mL GDF15 (Sino Biologicals) and 50 ng/mL SPP1 (GenTex), followed by cytokine treatment for 24 h. Recombinant GDF15 was previously tested for TGF-β contamination by ELISA, confirming absence of TGF-β in the sample.

EndoC-βH1 Human β Cell Line
EndoC-βH1 is a male, engineered cell line resulting from the lentiviral transfection of SV40LT expressed under the control of the insulin promoter (Ravassard et al., 2011). This cell line has been shown to respond to glucose stimulus by secreting insulin and it serves as an adequate model for studying cytokine-mediated β cell death (Gurgul-Convey et al., 2015; Gurgul-Convey et al., 2016).

EndoC-βH1 cells were obtained from Dr. R. Scharffmann (University of Paris, France) and cultured as described previously (Scharffmann et al., 2014). Briefly, EndoC-βH1 cells were maintained at 37°C and 5% CO2 atmosphere, and in DMEM media consisting of 1 g/L each of D-glucose and L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, 2% albumin from bovine fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, and 6.7 ng/mL sodium selenite. To study the protective effect of GDF15 and SPP1, we pretreated EndoC βH1 cells and human islets with human recombinant 100 ng/mL GDF15 (Sino Biologicals) and 50 ng/mL SPP1 (GenTex), followed by cytokine treatment for 24 h. Recombinant GDF15 was previously tested for TGF-β contamination by ELISA, confirming absence of TGF-β in the sample.

MIN6 Murine β Cell Line
MIN6 is a male, insulinoma-derived cell line from transgenic mice transfected with SV40 T-antigen that has the ability to secrete insulin on the presence of glucose (Ishihara et al., 1993).

MIN6 cells were maintained under standard culture conditions (Miyazaki et al., 1990). Briefly, MIN6 cells were maintained at 37°C and 5% CO2 atmosphere, and in DMEM media consisting of 4.5 g/L each of D-glucose and L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, 20 mM HEPES, and 50 μM 2-mercaptopoethanol.

Continued
Mice
5-week-old female NOD/ShiLTJ (NOD) mice were purchased from Jackson Laboratories and maintained as per the approved protocol from Indiana University Animal Care and Use Committee. Mice were housed in a standard 12 h light:dark cycle (6:00am-6:00pm) with a temperature range between 18-23°C. Mice were fed a standard chow diet (2018S, Harlan Laboratories). Health status was checked daily by veterinary technicians.

NOD mice spontaneously develop autoimmune diabetes with many similarities to human T1D, such as pancreas autoantibodies and autoreactive CD4+ and CD8+ T lymphocytes (Anderson and Bluestone, 2009).

Human Pancreas
Histological slices of human pancreata from cadaveric donors were kindly provided by the Network for Pancreatic Organ Donors with Diabetes (nPOD) (Pugliese et al., 2014). Because the tissues came from cadaveric donors, the study was not considered human subjects research, and no consent was required.

The characteristics of the tissue donors are listed in Table S4. The mean and standard deviation in age of the donors was 39.3 ± 9.9 years for control individuals (n = 3 male and 5 female), 32.9 ± 5.3 for type 1 diabetic individuals (n = 4 male and 6 female), and 45.6 ± 8.1 for type 2 diabetic individuals (n = 2 male and 2 female). The mean and standard deviation in BMI of the donors was 26.5 ± 5.3 for control individuals, 25.5 ± 3.9 for type 1 diabetic individuals, and 34.6 ± 6.7 for type 2 diabetic individuals.

An analysis of the influence of sex on the results of the study was not performed.

METHOD DETAILS
Pancreatic Islet Culture and Treatment
The islet cultures were cultured as described above, left to recover overnight and then treated with cytokines by adding fresh medium containing 50 U/mL IL-1β and 1000 U/mL IFN-γ, or left untreated by adding fresh medium without cytokines, and cultured for 24 h. Treated islets were collected into microcentrifuge tubes and washed twice by adding PBS containing 1% phosphatase inhibitor cocktail (Thermo Fisher Scientific) and 10 mM NaF (Sigma Aldrich), spinning at 1200 rpm at 4°C for 2 min and discarding the supernatant. Samples were then flash frozen with liquid N2 and stored at −80°C before processing.

Proteomic Analysis Using Tandem Mass Tags
Samples were submitted to Metabolite, Protein and Lipid Extraction (MPEX), as previously described (Nakayasu et al., 2016). Briefly, 300-500 treated or control islets from the same 10 donors were resuspended in milliQ water, and 5 volumes of 2:1 (v:v) chloroform:methanol solution was added. The samples were then incubated on ice for 5 min, vigorously vortexed for 1 min and centrifuged at 12,000 rpm at 4°C for 10 min. The protein disk was collected and washed by adding cold (−20°C) methanol and centrifuging at the same conditions, while the lipid and metabolite fractions were isolated and saved for future analyses. Protein pellets were then dried in a vacuum centrifuge and dissolved in 50 mM NH4HCO3 containing 8 M urea and 10 mM dithiothreitol. After incubating for 1 h at 37°C with shaking at 800 rpm, 400 mM iodoacetamide was added to a final concentration of 40 mM, and the mixture incubated for another h at the same conditions. The reaction mixture was then diluted 8 folds with 50 mM NH4HCO3, and 1 M CaCl2 was added to a final concentration of 1 mM. Proteins were digested for 5 h at 37°C using trypsin at 1:50 enzyme:protein ratio. Digested peptides were desalted by solid-phase extraction using C18 cartridges (Discovery, 50 mg, Sulpelco) and dried in a vacuum centrifuge. Peptides were then labeled and sorted into 2 sets of tandem mass tags (TMT-10plex, Thermo Fisher Scientific) following the manufacturer’s recommendations and desalted again using C18 cartridges. Labeled peptides were fractionated into 24 fractions using high-pH reversed phase chromatography, dried in a vacuum centrifuge and resuspended in 0.1% formic acid (Wang et al., 2011).

Peptides were analyzed on a Waters NanoAquity UPLC system with a custom packed C18 column (70 cm × 75 μm i.d., Phenomenex Jupiter, 3 μm particle size, 300 Å pore size) coupled with a Q-Exactive mass spectrometer (Thermo Fisher Scientific). Peptide separation was carried out with a gradient of water (solvent A) and acetonitrile (solvent B) both containing 0.1% formic acid (1%–8% B in 2 min, 8%–12% B in 18 min, 12%–30% B in 55 min, 30%–45% B in 22 min, 45%–95% B in 3 min, hold for 5 min in 95% B and 99%–1% B in 10 min). Eluting peptides were directly analyzed by nanoelectrospray ionization and full-MS scans were collected over 400–2000 m/z at a resolution of 35,000 at 400 m/z. The top 12 most intense parent ions were submitted to high-energy collision induced dissociation (HCD) fragmentation (2.0 m/z isolation width; 30% normalized collision energy; 17,500 resolution at 400 m/z), before being dynamically excluded for 30 s.

Tandem mass spectra were converted to DTA peak lists using Decon2LS_V2 (Mayampurath et al., 2008) combined with DTAREfinery (Petryuk et al., 2010), both using default parameters. MS/MS (Kim and Pevzner, 2014) was then used to search peptide spectra against islet protein sequences deposited on the RNAseq data from a previous study (Eizirik et al., 2012) deposited in RefSeq and supplemented with keratin sequences (32,780 total protein sequences). As searching parameters, the parent ion mass tolerance was set at 10 ppm, trypptic digestion in at least one of the termini was considered, and 2 missed cleavages were allowed. Cysteine carbamidomethylation and N-terminal/lysine TMT addition were searched as static modifications, whereas methionine oxidation was set as variable modification. Spectral-peptide matches were first filtered using a MSGF+ probability ≤ 1.0E−9, and then further filtered at protein level with a probability ≤ 1.0E−10, resulting in < 1% false-discovery rate.
**Label-free Proteomic Analysis**

Approximately 150 treated or control islets from 2 independent donors were obtained from IIDP as described above, and digested with trypsin using trifluoroethanol as a denaturing agent (Wang et al., 2005). Peptides were fractionated into 12 fractions by high resolution reversed phase capillary liquid chromatography employing a nanoACQUITY UPLC® system (Waters Corporation, Milford, MA) equipped with an autosampler. Capillary columns, 200 μm i.d. x 50 cm long, were packed with 3 μm Jupiter C18 bonded particles (Phenomenex, Torrence, CA). Separations were performed at a flow rate of 3.3 μL/min using a binary pump system, with 10 mM ammonium formate (pH 10.0) as mobile phase A and 10 mM ammonium formate in 90% acetonitrile (pH 10.0) as mobile phase B. 45 μL of peptide mixtures (0.5 μg/μL) were loaded onto the column and separated using a binary gradient of 5%–15% B in 15 min, 15%–25% B in 25 min, 25%–45% B in 25 min, and 45%–90% B in 38 min. The eluate was collected in 96 fractions and further concatenated into 12 samples, which were then individually analyzed by LC-MS/MS as described above. The data were processed with MaxQuant v.1.5.3.28 (Tyanova et al., 2016) by searching against the protein sequence database described above, and considering trypsin digestion specificity in at least one of the peptide termini, methionine oxidation as variable modification and cysteine carboxymethylation as fixed modification. The ion mass tolerance was set at 20 and 4.5 ppm for the first and main peptide searches. The data were filtered at 1% false-detection rate in both peptide-spectrum matches and protein levels. Then the quantification was performed by label-free quantification using default parameters.

**Western Blotting**

After cytokine treatment the human islets, EndoC-βH1 cells and MIN6 cells were harvested and lysed with lysis buffer and protein content was determined using the Lowry method. A total of 20 μg of protein per sample was electrophoresed on 4%–20% Bis-Tris gels (Bio-Rad) under denaturing conditions and blotted onto a PVDF membrane. The blots were blocked and probed for the following primary antibodies with overnight incubation at 4 °C: cleaved caspase 3 (Cell Signaling; 1:1000), Caspase 3 (1:1000), GDF15 (Bios; 1:500), SPP1 (Thermo Fisher Scientific; 1:1000), β-tubulin (Cell Signaling; 1:2000), Li-Cor anti-rabbit or anti-mouse (1:10000) secondary antibodies were used for the quantification of protein expression. The data were quantified using ImageStudio (LI-COR).

**Caspase 3/7 Activity and Flow Cytometry Assay to Measure Apoptosis**

Caspase-Glo 3/7 assay kit (Promega) was used to analyze caspase activity. Briefly, human islets were pre-exposed to 100 ng/mL rGDF15 or 50 ng/mL rSPP1 for 24 h and treated or not with 50 U/mL IL-1β and 1000 U/mL IFN-γ for additional 24 h. After the treatment period 25 islets per well with similar size were handpicked and suspended in 1:1 ratio of culture media to caspase-Glo reagent (100 μL of media + 100 μL of caspase-Glo reagent) in a 96 well plate and incubated for 1 h. The samples were read in a luminescent plate reader and the values were represented as relative luminescence units (RLU) of caspase 3/7 activity. We also measured cell viability by flow cytometry (BD, FACScantoll) using the apoptotic (annexin V) and viability (7AAD) (BD Annexin AS FITC/7-AAD Kit) markers. Briefly, human islets were dissociated by incubating them with 1mL of Accutase (edmillipore) and 1ul of DNase I (edmillipore) at 37 °C for 10 min. After 10 min of incubation, 0.1% of BSA-PBS was added to stop the reaction and the cells were then washed twice with PBS and cultured overnight with islet culture media. After overnight culture the islets were replenished with fresh culture media and treated with or without rGDF15 and rSPP1 as mentioned above. On the day of measurement, the cells were washed twice with 0.1% BSA-PBS and incubated for 20 min at 37 °C in KRBS buffer supplemented with 3.3 mM D-glucose and annexin V-FITC and 7-AAD and then analyzed using BD FACScantoll.

**Quantitative RT-PCR**

Total RNA was isolated using RNEasy plus mini kit (QIAGEN) as per the manufacturer’s protocol. Reverse transcription was performed using M-MLV RT kit (Invitrogen) and qRT-PCR was performed using TaqMan probe-based approach (Applied Biosystems). TaqMan primer were used for the quantification GDF15 and SPP1 messenger RNA expression and β-actin was used as a housekeeping control for the normalization and the data were expressed as relative fold expression against untreated control samples.

**Polyribosomal Profiling**

Polyribosomal profiling studies were performed using untreated and IL-1β + IFN-γ treated human EndoC-βH1 cells. Briefly, cells were lysed and centrifuged on a 10%–50% sucrose gradient. BioComp piston gradient fractionator connected with an in-line UV monitor (absorbance 254 nm) was used to determine the RNA and gradients were collected in ten 1mL fractions. Fractions from 1 to 5 were considered to be monoribosome-associated RNAs and fractions 6 to 10 were considered to be polyribosome-associated RNAs. PM ratio (polysomes to monosomes ratio) was calculated by area under the curve (AUC) of polysome fractions (more than two ribosomes) divided by area under the curve of monosome fractions (80S ribosome). Percentage of mRNA expression was calculated as described previously (Templin et al., 2014). P/M ratio for GDF15 mRNA was calculated by using total percentage of 6 to 10 polysome fractions divided by total percentage of 1 to 5 monosome fractions.

**Animal Studies**

For the insulitis study, NOD mice (n = 5) were acclimatized for one week and were then injected intraperitoneally every second day for two weeks with 0.5 mg/kg rGDF15 dissolved in water or water alone. Recombinant proteins were previously tested for TGF-β contamination by ELISA, confirming absence of TGF-β in the preparations. For the diabetes prevention study, we used 20 mice per group, which in previous studies from our group (Cabrera et al., 2013), was shown to provide a 95% power to detect an increase...
in non-diabetic proportion of 0.66 with a significance level (alpha) of 0.05 (two-tailed). NOD mice were acclimatized for one week and then beginning at 6 weeks of age were injected intraperitoneally (IP) every 2 days for 4 weeks with 0.5 mg/kg rhGDF15 dissolved in saline or saline alone. Mice were monitored for 24 weeks, until > 80% of the control group developed diabetes (blood glucose level > 250 mg/mL on two separate occasions. Body weight and blood glucose were monitored as previously described (Maganti et al., 2016). Mice were euthanized and pancreata were harvested at the end of the different experiments.

**Immunohistochemistry/Immunofluorescence**

Pancreata were fixed with 4% PFA at room temperature for 4 h, paraffin embedded, and immunostaining was performed as previously described (Evans-Molina et al., 2009) using the following antibodies: insulin (Santa Cruz) and counter stained with peroxidase conjugated anti-rabbit IgG (Vector). Insulitis was scored from immunohistochemical staining as described previously (Tersey et al., 2014) using at least 3 pancreas sections 70 μm apart from 5 mice per group and the images were acquired using an EVOIS XL Core microscope (Life Technologies). For studies using immunofluorescence we used the following primary antibodies: insulin (Dako; 1:400), GDF15 (Bio-sss; 1:200), SPP1 (Thermo Fisher Scientific; 1:200), 4-HNE (Abcam; 1:200), glucagon (Abcam; 1:300) and counter stained with following secondary antibodies: goat anti-guinea pig (Alexa 488; 1:400), donkey anti-rabbit (Alexa-568; 1:250) and donkey anti-mouse (Alexa-647; 1:300). The images were acquired using LSM 800 confocal microscope (Carl Zeiss, Germany). Experiments without the primary antibody and with a competition assay by adding recombinant protein were run in parallel to assess the specificity of the staining.

**Quantitative and Statistical Analysis**

**Quantitative and Pathway Analysis of TMT-labeled Proteomic Analysis**

For quantification, TMT reporter ion intensities of confidently identified peptides were extracted with MASIC (Monroe et al., 2008). Then intensities of reporter ions of peptides with multiple MS/MS spectra were summed together to remove redundancy and increase signal-to-noise ratios. Quality control processing of the proteomics data include sample-level outlier evaluation using a robust Principal Component Analysis (Webb-Robertson et al., 2011) and total sample abundance normalization with median centering (Callister et al., 2006; Webb-Robertson et al., 2011). No sample-level issues were identified. Proteins were quantified with a standard reference-based quantification (Taverner et al., 2012; Wang et al., 2013). The Bioconductor analysis package limma (Ritchie et al., 2015) was used to identify proteins differentially expressed in each of the two TMT sets, using the paired samples setting. Statistical power was calculated based on a two-sided paired t test with a type one error rate, α, of 0.05 using the “samplesizepwr” function in MATLAB R2018a. The standard deviation was computed for each protein from the control group for both set 1 and set 2, 10,621 and 11,404 proteins, respectively. Normality of the proteomics data was evaluated with a Kolmogrov-Smirnov test of normality and in all cases less than 5% failed to meet our assumptions of normality.

The DAVID online resource (http://david.ncifcrf.gov) was then used to obtain functional enrichment of up- and downregulated proteins. Only enriched functions from KEGG database was used for plotting the pathway network with Enrichment Map tool (Merico et al., 2010). Physical/regulatory interactions among differentially abundant apoptotic proteins were mapped with Metacore pathway analysis software (Thomson Reuters) using the gene ontology process “regulation of apoptotic processes.”

**Image Processing and Quantification**

For quantification of immunofluorescence experiments, human pancreatic sections were examined by acquiring Z stacks images using confocal microscopy (Carl Zeiss Microscopy, Germany). Fluorescence intensity of the images was quantified by using ImageJ (NIH) as described elsewhere (Sun et al., 2016). Briefly, from each pancreatic section, 5-10 islets were randomly selected, and the islet areas (number of pixels) and their integrated densities were then measured. Background fluorescence intensity was measured for each islet and the corrected total islet cell fluorescence was calculated by the following formula: Total Islet Cell Fluorescence (CTCF) = Integrated Density - (Area of selected cell X Mean fluorescence of background). All image analyses were performed in a blinded fashion and independently by two individuals.

**Statistical Analysis of Other Experiments**

Besides the proteomic analysis, statistical test of all the other experiments were performed with GraphPad Prism (GraphPad Software). For most of the experiments, results were considered significant when p \( \leq 0.05 \) for Student’s t test (two-tailed, unpaired). For the proteomics versus transcriptomics comparison a two-tailed Fisher’s exact was used and considered significant with p \( \leq 0.05 \) cutoff. For the image quantitative analysis, an one-way ANOVA test was used and considered significant with p \( \leq 0.05 \). For NOD mouse diabetes outcome experiments, a log-rank (Mantel-Cox) test was used to determine significance between control- and rhGDF15-treated groups. Normality of data was evaluated with a Kolmogrov-Smirnov test of normality and in all cases less than 5% failed to meet our assumptions of normality.

For all statistical analyses, the parameters can be found in the figures and figure legends, as applicable.

**DATA AND CODE AVAILABILITY**

The raw LC-MS/MS proteomics data files were deposited in the ProteomeXchange-associated Pride data repository under the accession number PXD009131.